Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co | Buenos Aires | Healthcare | Pharmaceuticals | ARS 649.20T | 77.8x | 1.19 | ARS 14,450 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 370.18T | 25.3x | ARS 1,340 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Johnson & Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 370.18T | 25.3x | -0.46 | ARS 11,525 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Buenos Aires | Healthcare | Pharmaceuticals | ARS 370.03T | 25.3x | -1.32 | ARS 815 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Buenos Aires | Healthcare | Pharmaceuticals | ARS 293.39T | 57.8x | -2.68 | ARS 18,825 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 245.09T | 20.2x | 0.12 | ARS 21,800 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 205.65T | 11.8x | 0.13 | ARS 29,275 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 195.87T | 30.1x | 3.07 | ARS 35,975 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Buenos Aires | Healthcare | Pharmaceuticals | ARS 149.62T | 35.4x | -0.81 | ARS 10,475 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 140.67T | 33.2x | -0.55 | ARS 7,000 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 115.02T | -15.8x | 0.08 | ARS 21,500 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Buenos Aires | Healthcare | Pharmaceuticals | ARS 108.17T | 877.8x | -8.96 | ARS 25,150 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 67.13T | 21x | -0.36 | ARS 9,320 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | Buenos Aires | Healthcare | Pharmaceuticals | ARS 29T | 22.8x | 0.04 | ARS 45,225 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen AR | Buenos Aires | Healthcare | Pharmaceuticals | ARS 22.98T | 14.2x | 1.44 | ARS 13,750 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laboratorios Richmond | Buenos Aires | Healthcare | Pharmaceuticals | ARS 151.81B | 8.2x | 0.02 | ARS 1,880 | 8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Instituto Rosenbusch | Buenos Aires | Healthcare | Pharmaceuticals | ARS 4.43B | 4.4x | 0.01 | ARS 104 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |